Lifemd Inc (LFMD) Stock Price, Quote & News

Company Profile

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides vi...

Industry: Health Information Services

Sector: Healthcare

Phone: 866 351 5907

Website: lifemd.com

Address:

236 Fifth Avenue, Suite 400, New York, United States

MarioAndretti Jun. 4 at 9:33 PM

$LFMD $HYLN cha ching

0 · Reply

TaoistTrader Jun. 4 at 3:31 PM

$LFMD traded at 14.76 last June remember?

0 · Reply

TaoistTrader Jun. 3 at 11:17 AM

$LFMD getting primed for break out

0 · Reply

LeeEnnisEA Jun. 2 at 6:54 PM

$LFMD found decent premium in July for $7.00 🤗

1 · Reply

rolypoly101 Jun. 2 at 3:00 PM

$LFMD The price action on this looks like it's building up for another big run. Also looking at the 5 year chart, looks to be about time for the next rise. If Q2 shows positive EBITA and a rev beat, I think we're set for another run.

0 · Reply

MarioAndretti Jun. 2 at 2:37 PM

$LFMD cha Ching

0 · Reply

MarioAndretti Jun. 1 at 11:19 PM

$LFMD I didn’t come here for this bullshit give me 8

1 · Reply

TaoistTrader May. 28 at 6:59 PM

$LFMD starting to look good

0 · Reply

Alex1965 May. 28 at 4:28 AM

$LFMD" Women’s health patient signups achieved 657% quarter-over-quarter growth with approximately 70% reduction in customer acquisition costs. The majority of revenue was derived from recurring subscriptions, according to management. The company provided guidance for second-quarter fiscal 2026 revenue in the range of $47 million to $50 million, with adjusted EBITDA between negative $2 million and positive $1 million. Full-year fiscal 2026 revenue guidance remained at $220 million to $230 million, with adjusted EBITDA of $12 million to $17 million. According to InvestingPro analysis, the stock appears undervalued at current levels, trading at $4.24 compared to its Fair Value estimate."

0 · Reply

MarioAndretti May. 27 at 11:32 PM

$HYLN $LFMD Buy stocks that’s are beaten down and can’t be beat anymore it’s a long way to recovery up 400% on both. Clear reversal

0 · Reply

LifeMD appoints Umesh Sripad as chief technology officer

Jun 1, 2026, 8:05 AM EDT - 3 days ago

LifeMD Appoints Umesh Sripad as Chief Technology Officer

LFMDP

May 19, 2026, 12:00 PM EDT - 16 days ago

LifeMD Transcript: 16th Annual LD Micro Invitational Conference

May 15, 2026, 8:00 AM EDT - 20 days ago

LifeMD to Participate in Upcoming Investor Conferences

LFMDP

May 7, 2026, 7:00 AM EDT - 4 weeks ago

LifeMD Slides: Investor presentation

2026-05-07T00:47:06.000Z - 4 weeks ago

LifeMD reports Q1 EPS (20c), consensus (12c)

2026-05-07T00:46:21.000Z - 4 weeks ago

LifeMD sees Q2 revenue $47M-$50M, consensus $53.74M

2026-05-07T00:45:57.000Z - 4 weeks ago

LifeMD backs FY26 revenue view $220M-$230M, consensus $223.59M

May 6, 2026, 4:30 PM EDT - 4 weeks ago

LifeMD Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

LifeMD Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

LifeMD Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

LifeMD Quarterly report: Q1 2026

May 6, 2026, 4:05 PM EDT - 4 weeks ago

LifeMD Reports First Quarter 2026 Results

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

LifeMD Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

LifeMD Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

LifeMD Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

LifeMD to Report First Quarter 2026 Financial Results on May 6

LFMDP

2026-04-24T17:05:27.000Z - 5 weeks ago

LifeMD management to meet with BTIG

2026-04-10T12:26:19.000Z - 7 weeks ago

LifeMD now offering Foundayo from Eli Lilly

LLY

Apr 10, 2026, 8:15 AM EDT - 7 weeks ago

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LFMDP

2026-03-31T14:25:15.000Z - 2 months ago

LifeMD announces launch of Wegovy subscription program

NVO

Mar 31, 2026, 8:45 AM EDT - 2 months ago

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

LFMDP

Mar 24, 2026, 4:05 PM EDT - 2 months ago

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LFMDP

2026-03-17T15:41:34.000Z - 2 months ago

LifeMD management to meet virtually with B. Riley

Mar 16, 2026, 8:00 AM EDT - 2 months ago

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

2026-03-16T08:40:05.000Z - 2 months ago

LifeMD upgraded to Outperform from Neutral at Mizuho

2026-03-12T14:11:07.000Z - 3 months ago

LifeMD price target raised to $10 from $8 at Freedom Capital

2026-03-11T10:15:39.000Z - 3 months ago

LifeMD price target raised to $10 from $9 at H.C. Wainwright

Mar 9, 2026, 4:30 PM EDT - 3 months ago

LifeMD Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 3 months ago

LifeMD Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 3 months ago

LifeMD Earnings release: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 3 months ago

LifeMD Slides: Q4 2025

2026-03-09T20:21:55.000Z - 3 months ago

LifeMD reports Q4 EPS 41c, consensus 3c

2026-03-09T20:21:26.000Z - 3 months ago

LifeMD sees Q1 revenue $48M-$49M, consensus $45.61M

2026-03-09T20:20:41.000Z - 3 months ago

LifeMD sees FY26 revenue $220M-$230M, consensus $222.64M

Mar 9, 2026, 4:05 PM EDT - 3 months ago

LifeMD Reports Fourth Quarter and Full Year 2025 Results

LFMDP

Mar 3, 2026, 4:05 PM EST - 3 months ago

LifeMD to Participate in Two Investor Conferences During March

LFMDP

Feb 23, 2026, 8:00 AM EST - 3 months ago

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

LFMDP

2026-01-06T13:47:34.000Z - 5 months ago

LifeMD closes $50M revolving credit facility

Jan 6, 2026, 8:30 AM EST - 5 months ago

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

LFMDP

2026-01-05T13:36:18.000Z - 5 months ago

LifeMD expands collaboration with Novo Nordisk for Wegovy pill

NVO

Jan 5, 2026, 8:05 AM EST - 5 months ago

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

LFMDP

Nov 24, 2025, 8:00 AM EST - 6 months ago

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

2025-11-19T16:30:10.000Z - 7 months ago

LifeMD price target lowered to $9 from $13 at H.C. Wainwright

Nov 17, 2025, 4:30 PM EST - 7 months ago

LifeMD Earnings Call Transcript: Q3 2025

Nov 17, 2025, 4:30 PM EST - 7 months ago

LifeMD Quarterly report: Q3 2025

Nov 17, 2025, 4:30 PM EST - 7 months ago

LifeMD Earnings release: Q3 2025

Nov 17, 2025, 4:30 PM EST - 7 months ago

LifeMD Slides: Q3 2025

Nov 17, 2025, 4:05 PM EST - 7 months ago

LifeMD Reports Third Quarter 2025 Results

LFMDP

Nov 17, 2025, 8:00 AM EST - 7 months ago

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

LFMDP

Nov 10, 2025, 8:00 AM EST - 7 months ago

LifeMD to Participate in the BTIG Digital Health Forum

LFMDP

Nov 5, 2025, 5:15 PM EST - 7 months ago

LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

LFMDP

Nov 4, 2025, 9:15 AM EST - 7 months ago

LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform

LFMDP

Oct 23, 2025, 8:00 AM EDT - 8 months ago

LifeMD to Report Third Quarter 2025 Financial Results on November 6

Oct 22, 2025, 8:00 AM EDT - 8 months ago

LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program

Sep 30, 2025, 8:14 AM EDT - 8 months ago

LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers

NVO

Sep 30, 2025, 8:00 AM EDT - 8 months ago

LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk

Sep 25, 2025, 4:06 PM EDT - 9 months ago

LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

LFMDP

MarioAndretti Jun. 4 at 9:33 PM

$LFMD $HYLN cha ching

0 · Reply

TaoistTrader Jun. 4 at 3:31 PM

$LFMD traded at 14.76 last June remember?

0 · Reply

TaoistTrader Jun. 3 at 11:17 AM

$LFMD getting primed for break out

0 · Reply

LeeEnnisEA Jun. 2 at 6:54 PM

$LFMD found decent premium in July for $7.00 🤗

1 · Reply

rolypoly101 Jun. 2 at 3:00 PM

0 · Reply

MarioAndretti Jun. 2 at 2:37 PM

$LFMD cha Ching

0 · Reply

MarioAndretti Jun. 1 at 11:19 PM

$LFMD I didn’t come here for this bullshit give me 8

1 · Reply

TaoistTrader May. 28 at 6:59 PM

$LFMD starting to look good

0 · Reply

Alex1965 May. 28 at 4:28 AM

0 · Reply

MarioAndretti May. 27 at 11:32 PM

$HYLN $LFMD Buy stocks that’s are beaten down and can’t be beat anymore it’s a long way to recovery up 400% on both. Clear reversal

0 · Reply

Finanz May. 27 at 8:13 PM

$LFMD https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-lifemd-stock-cites-subscriber-growth-93CH-4712005?ampMode=1

0 · Reply

MorganHoratio May. 22 at 6:44 PM

5 MICRO-CAP STOCKS I’LL BE MONITORING IN MAY (Updated May 22, 2026) $SLNH - ~$1.81 Up +9% from the original $1.66 post. $PLUG - ~$3.83 Up +22% from the original $3.13. $IOVA - ~$4.07 Up +21% from the original $3.36. $FCEL - ~$25.70 Up +98% from the original $13.00. $LFMD - ~$4.28 Down -9% from the original $4.68. An absolute masterclass of a micro-cap watchlist! May isn't even over, and the explosive velocity here is sending risk appetite through the roof. Breaking down these high-beta runners: The Clean Energy Surge: $FCEL's jaw-dropping 98% run and $PLUG's 22% spike stole the show, fully fueled by the massive data center power crunch. Alpha Elasticity: $SLNH continues to grind higher as an AI compute underdog, paired with a solid 21% gain on $IOVA, while $LFMD's minor dip offers a tactical pullback. When liquidity rotates into micro-caps, the gains are swift and unforgiving. Which of these May champions has the legs to carry this momentum into June? Drop your high-conviction tickers below!

1 · Reply

Alex1965 May. 22 at 1:29 AM

$LFMD How does Lilly’s next-gen obesity drug compare to Novo’s https://seekingalpha.com/news/4595976-how-does-lilly-s-next-gen-obesity-drug-compare-to-novo-s?utm_content=link-4&position=rta_news_sublogic_default_main_2_textlink&utm_source=seeking_alpha&utm_campaign=rta-stock-news&messageid=2900&mailingid=45829223&serial=45829223.13123&utm_term=45829223.13123&source=email_2900&utm_medium=email

0 · Reply

MorganHoratio May. 21 at 4:46 PM

Our team has compiled a list of the best companies in various industries: Health 1. $OSCR 2. $LLY 3. $UNH Which other companies do you think have not been included? This list completely anchors healthcare’s elite growth and defensive moats! $OSCR (crushing its Q1 with an 84% EPS blowout), $LLY (the reigning pharma king, raising guidance on a 56% Q1 revenue spike), and legacy titan $UNH make a stellar institutional trio. However, missing next-gen innovation and GLP-1 alternatives leaves a massive gap. Where is $LFMD (LifeMD), the explosive telehealth disruptor capturing the affordable weight-loss boom? And don't overlook $CCLD, fresh off its Nasdaq Analyst Day scaling as an AI-first healthcare infrastructure engine. Time to weigh in! In this polarized healthcare tape, are you sticking with high-premium giants like $LLY, or hunting for explosive, high-beta digital health dark horses like $OSCR and $LFMD? Drop your favorite tickers below! 👇

0 · Reply

RichMahogany May. 21 at 4:39 PM

$LFMD glad I held off on jumping back in after selling at the high lol

0 · Reply

MarioAndretti May. 20 at 4:43 PM

$LFMD Amazon BO!!!!! Fuck $HIMS

0 · Reply

IndependentWatch5 May. 20 at 10:31 AM

$LFMD is this the run for 10/12 happening

0 · Reply

MorganHoratio May. 19 at 10:15 PM

5 MICRO-CAP STOCKS I’LL BE MONITORING IN MAY (Updated May 19, 2026) $SLNH - ~$1.83 (Up +10% from the original $1.66 post.) $PLUG - ~$3.31 (Up +6% from the original $3.13.) $IOVA - ~$3.46 (Up +3% from the original $3.36.) $FCEL - ~$17.36 (Up +34% from the original $13.00.) $LFMD - ~$4.30 (Down -8% from the original $4.68.) This micro-cap watchlist is delivering pure alpha, perfectly timing May’s liquidity rotation! $FCEL absolute crushed it, locking in a +34% explosive move. As the AI scaling bottleneck shifts strictly to the power grid, off-grid infrastructure is turning into an immediate necessity. This structural tailwind is boosting high-beta plays like $PLUG and crypto-miner infrastructure $SLNH. Meanwhile, $IOVA stabilizes inside its accumulation zone, and $LFMD's -8% dip presents a tactical entry window. Micro-caps are all about asymmetric risk. Which of these five hyper-growth runners finishes May as the ultimate multi-bagger winner? Drop your tickers!

0 · Reply

Alex1965 May. 19 at 5:31 PM

$LFMD https://seekingalpha.com/news/4594635-trumprx-set-expand-into-generic-medicines-mark-cuban?utm_content=link-1&position=rta_news_sublogic_default_main_0_title&utm_source=seeking_alpha&utm_campaign=rta-stock-news&messageid=2900&mailingid=45766632&serial=45766632.16652&utm_term=45766632.16652&source=email_2900&utm_medium=email

0 · Reply

MarioAndretti May. 19 at 2:06 PM

$LFMD Conference glad we broke away from $HIMS they got tons more room for a drop off

1 · Reply

MarioAndretti May. 19 at 1:48 PM

$LFMD Can’t be a dead horse red days are normal

0 · Reply

TaoistTrader May. 19 at 10:08 AM

$APLD $CRWV $IREN $LFMD sell in May and go away? Lightened up again significantly yesterday. Temporarily

0 · Reply

Market Cap	226.82M
Revenue (ttm)	194.06M
Net Income (ttm)	14.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	7.39%
Debt to Equity Ratio	0.00

Volume	968,200
Avg Vol	1,058,166
Day's Range	N/A - N/A
Shares Out	48.36M
Stochastic %K	84%
Beta	1.98
Analysts	Strong Sell
Price Target	$9.88